Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT

被引:32
作者
Conti, F. [1 ]
Perricone, C. [1 ]
Reboldi, G. [2 ]
Gawlicki, M. [3 ]
Bartosiewicz, I. [1 ]
Pacucci, V. A. [1 ]
Massaro, L. [1 ]
Miranda, F. [1 ]
Truglia, S. [1 ]
Alessandri, C. [1 ]
Spinelli, F. R. [1 ]
Teh, L-S [4 ]
Ceccarelli, F. [1 ]
Valesini, G. [1 ]
机构
[1] Sapienza Univ Roma, Dipartimento Med Interna & Specialita Med, Lupus Clin, I-00161 Rome, Italy
[2] Univ Perugia, Dept Med, I-06100 Perugia, Italy
[3] Corp Translat Inc, E Hartford, CT USA
[4] Royal Blackburn Hosp, Dept Rheumatol, Blackburn, Lancs, England
关键词
Autoimmunity; SF-36; systemic lupus erythematosus; quality of life; LupusQoL; lupus; autoantibodies; CRITERIA; TRIALS; UPDATE; NUMBER; SF-36;
D O I
10.1177/0961203314524466
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of this paper is to assess the validity of a linguistically validated version of the Lupus Quality of Life (LupusQoL (c)) in Italian patients affected by systemic lupus erythematosus (SLE). Methods: Consecutive SLE patients completed the Italian version of the LupusQoL (c) and the Short Form (SF)-36. Disease activity was evaluated by the SLE disease activity Index-2000 (SLEDAI-2 K), and chronic damage by the Systemic Lupus International Collaborating Clinics/American College Rheumatology (ACR) Damage Index score (SDI). Internal consistency and test-retest reliability, convergent and discriminant validity were examined. Factor analysis with varimax rotation was performed. Results: A total of 117 Italian SLE patients (M: F 13: 104; mean age 40.6 +/- 11.6 years, mean disease duration 127.5 +/- 94.1 months) were recruited into the study. The Italian version of the LupusQoL (c) demonstrated substantial evidence of convergent validity in these patients when compared with equivalent items of the SF-36. In addition, the LupusQoL (c) discriminated between patients with different degrees of disease activity as measured by the SLEDAI-2 K. SLE patients with higher disease activity (SLEDAI-2K >= 4) showed poor QoL compared with those with lower disease activity (SLEDAI-2K< 4), with significant differences in the domains of physical health, planning, burden to others and fatigue (p = 0.001, p = 0.04, p = 0.03, p 0.04, respectively). The confirmatory factor analysis using the eight domain loadings of the 34 items showed a poor fit (chi(2) /degree of freedom (df) 2.26, chi(2) = 1128.6 (p < 0.001), root mean square error of approximation (RMSEA) = 0.167; goodness-of-fit index (GFI) = 0.606, comparative fit index (CFI) = 0.649)). Screeplot analysis suggested a five-factor loading structure and confirmatory factor analysis result of which is similar to the eight-factor model. A good internal consistency was observed (Cronbach's a 0.89-0.91). Test-retest reliability was good to excellent between baseline and day 15 (intraclass correlation coefficient (ICC) 0.90-0.98). Conclusion: The Italian version of the LupusQoL (c) is a valid tool for adult patients with SLE.
引用
收藏
页码:743 / 751
页数:9
相关论文
共 29 条
[1]   EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints [J].
Bertsias, G. K. ;
Ioannidis, J. P. A. ;
Boletis, J. ;
Bombardieri, S. ;
Cervera, R. ;
Dostal, C. ;
Font, J. ;
Gilboe, I. M. ;
Houssiau, F. ;
Huizinga, T. ;
Isenberg, D. ;
Kallenberg, C. G. M. ;
Khamashta, M. ;
Piette, J. C. ;
Schneider, M. ;
Smolen, J. ;
Sturfelt, G. ;
Tincani, A. ;
van Vollenhoven, R. ;
Boumpas, D. T. ;
Gordon, C. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (04) :477-483
[2]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[3]   COMPREHENSIVE TRIAL OF SCREE AND KG CRITERIA FOR DETERMINING NUMBER OF FACTORS [J].
CATTELL, RB ;
VOGELMANN, S .
MULTIVARIATE BEHAVIORAL RESEARCH, 1977, 12 (03) :289-325
[4]   Flare, Persistently Active Disease, and Serologically Active Clinically Quiescent Disease in Systemic Lupus Erythematosus: A 2-Year Follow-Up Study [J].
Conti, Fabrizio ;
Ceccarelli, Fulvia ;
Perricone, Carlo ;
Miranda, Francesca ;
Truglia, Simona ;
Massaro, Laura ;
Pacucci, Viviana Antonella ;
Conti, Virginia ;
Bartosiewicz, Izabella ;
Spinelli, Francesca Romana ;
Alessandri, Cristiano ;
Valesini, Guido .
PLOS ONE, 2012, 7 (09)
[5]   Neurocognitive Dysfunction in Systemic Lupus Erythematosus: Association with Antiphospholipid Antibodies, Disease Activity and Chronic Damage [J].
Conti, Fabrizio ;
Alessandri, Cristiano ;
Perricone, Carlo ;
Scrivo, Rossana ;
Rezai, Soheila ;
Ceccarelli, Fulvia ;
Spinelli, Francesca Romana ;
Ortona, Elena ;
Marianetti, Massimo ;
Mina, Concetta ;
Valesini, Guido .
PLOS ONE, 2012, 7 (03)
[6]   Rituximab treatment of systemic lupus erythematosus in controlled trials and in clinical practice: Two sides of the same coin [J].
Conti, Fabrizio ;
Perricone, Carlo ;
Ceccarelli, Fulvia ;
Valesini, Guido .
AUTOIMMUNITY REVIEWS, 2010, 9 (11) :716-720
[7]   LupusQoL-FR is valid to assess quality of life in patients with systemic lupus erythematosus [J].
Devilliers, Herve ;
Amoura, Zahir ;
Besancenot, Jean-Francois ;
Bonnotte, Bernard ;
Pasquali, Jean-Louis ;
Wahl, Denis ;
Maurier, Francois ;
Kaminsky, Pierre ;
Pennaforte, Jean-Loup ;
Magy-Bertrand, Nadine ;
Arnaud, Laurent ;
Binquet, Christine ;
Guillemin, Francis .
RHEUMATOLOGY, 2012, 51 (10) :1906-1915
[8]  
Diniz DP, 2006, SERIE GUIAS MED AMBU
[9]   QUALITY-OF-LIFE - ITS DEFINITION AND MEASUREMENT [J].
FELCE, D ;
PERRY, J .
RESEARCH IN DEVELOPMENTAL DISABILITIES, 1995, 16 (01) :51-74
[10]   Adaptation and validation of the Spanish version of a disease-specific quality of life measure in patients with systemic lupus erythematosus: The Lupus Quality of Life [J].
Gonzalez-Rodriguez, Viviana ;
Isabel Peralta-Ramirez, Maria ;
Navarrete-Navarrete, Nuria ;
Luis Callejas-Rubio, Jose ;
Santos Ruiz, Ana Maria ;
Khamashta, Munther .
MEDICINA CLINICA, 2010, 134 (01) :13-16